MSB

4.69%

$1.45 mesoblast limited

CEO Itescu needs to go, page-261

First 261 Last

Share
Profile

Follow
LeftYahoo

233 Posts.

3441

07/08/23

14:44

Post #: 69203348
Share

Originally posted by dolcevita: ↑

You're a seasoned analyst. That doesn't give you a monopoly on logic nor on this particular field.

See the Bell Potter analyst above who describes the FDA approach as 'confusing'. I think this is putting it mildly.

When I say that it's unethical to require a full adult trial I mean this in ALL the circumstances.

Which part of this did you not understand

You say that the patients are not abandoned. This is not good enough is it? Not when their mortality remains so massive.

Tell that to the patient, not to me. You are deprived of the best possible treatment, but don't worry, you will not be in pain and have palliative care.

You could be in the 20% that survives, give it a go?

THAT"S what I mean about ethics. But you conflate this into a generic and irresponsible claim that I am somehow against double blind clinical trials, presumably when I'm in the mood.

Not when there is a therapy that's already demonstrated to reverse the mortality rate.

Not when pharmaceutical drugs are waved through on lesser proof, with more damaging potential.

No. This is a stitch up.

Everyone has an ego and yours has been exposed.

Nothing you say justifies skewering Silviu Itescu at this crucial stage.

Sorry but you're now lead in the saddle and I never thought
a) I'd come into conflict with you,
b) that you'd get so personal and so insulting
c) that you'd be calling for SI's scalp
d) that you'd confuse statements that are about a range of possibilities, with statements of fact.
I have a legal background. Do not misrepresent my statements it is not appreciated.

Strange days, but I will leave the last words to Bell Potter. I think they sum up the inconsistencies well. They also left out the inconsistencies with the bewildering refusal to follow the 9-1 recommendations of the expert panel, which is why we are here.

What I am clear on is that the behaviour of the FDA is inconsistent at best. That we had legal avenues and followed them up, and will continue to do so.

Finally on abandonment. I regretted your decision to abandon us in this forum, and urged you to return. Suddenly at this crucial stage you now you decide to swoop back. You should have never left but your ego kept you away. I urged you to not over react to what happened.
Instead of restraint you are pouring oil on the fire.
You of all people must know that retail investors would
a) never have the numbers to cause a spill
b) sell in fright.

Retail investors are waking in fright but someone is mopping up their shares. You are not helping.

Don't lecture me about emotion.

Expand

Well... I would certainly never want to deprive a patient in need of "the best possible treatment". Tell me what that treatment is in these ADULT patients on complex evolving immuno-modulator regimens and post the phase 3 data to back your claim. Preferably from a peer-reviewed journal.

MSB Price at posting: 41.8¢ Sentiment: Sell Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

IMA

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

There are more pages in this discussion • 653 more messages in this thread...

First 261 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.45		Change 0.065(4.69%)		Mkt cap ! $1.655B

Open	High	Low	Value	Volume
$1.39	$1.50	$1.38	$7.016M	4.856M

Buyers (Bids)

No.	Vol.	Price($)
1	10425	$1.44

Sellers (Offers)

Price($)	Vol.	No.
$1.45	44243	5

View Market Depth

No.	Vol.	Price($)
1	10425	1.440
2	9000	1.435
4	62190	1.430
1	473	1.425
1	5000	1.420

Price($)	Vol.	No.
1.450	16999	2
1.455	17000	1
1.465	24896	3
1.470	112738	6
1.475	1800	1

Last trade - 16.10pm 11/10/2024 (20 minute delay)

MSB (ASX) Chart

CEO Itescu needs to go, page-261

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Cauldron Energy reports "excellent" uranium assays in latest drill run

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CEO Itescu needs to go, page-261

Top Stories

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Cauldron Energy reports "excellent" uranium assays in latest drill run

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News